DefiniGEN was founded to commercialise OptiDIFF, a stem cell production platform developed at the University of Cambridge. The company has now licensed CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard to develop human cell disease models, and will produce CRISPR-Cas9 gene edited cells, allowing their customers to take advantage of the power of genome editing, alongside world-leading stem cell production and disease modelling capabilities. The technology will be combined with DefiniGEN’s induced Pluripotent Stem Cell differentiation platform to generate preclinical cell models which can accelerate non-alcoholic steatohepatitis, Type 2 diabetes, and orphan liver disease drug discovery programmes.
“DefiniGEN licenses CRISPR-Cas9“
DefiniGEN’s CEO, Dr Marcus Yeo, said: “Through our license with Broad Institute, we are pleased to be able to enhance our customer’s research programs by offering state-of-the-art CRISPR-Cas9 gene edited disease model cell products and custom services.”